Brief by Shorts91 Newsdesk / 01:21pm on 16 May 2024,Thursday Health & Wellness
Recent research links AstraZeneca's Covishield vaccine to another rare blood disorder, Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT). Autoantibodies targeting platelet factor 4 (PF4) are identified as the culprit. This discovery adds to existing concerns regarding the vaccine's safety profile. Scientists stress the importance of continued monitoring and investigation into potential adverse effects. The findings underscore the complexity of vaccine-related complications and highlight the necessity of thorough safety evaluations in vaccine development and administration.
